AMD Therapy

September 19, 2022

Aflibercept 8mg Extended Injection Interval Set to Reduce Treatment Burden for nAMD and DME

Not only is neovascular (wet) age-related macular degeneration (nAMD) one of the leading causes of vision impairment around the world,…

September 15, 2022

Lowering Treatment Burden and Maintaining Vision Gains with Aflibercept

The introduction of anti-vascular endothelial growth factor (anti-VEGF) therapy revolutionized the management and treatment of exudative retinal diseases — and…

EURETINA 2022 LIVE Coverage: Real-World Evidence Registries in Ophthalmology

September 19, 2022

Aflibercept 8mg Extended Injection Interval Set to Reduce Treatment Burden for nAMD and DME

September 15, 2022

Lowering Treatment Burden and Maintaining Vision Gains with Aflibercept

Aflibercept 8mg Extended Injection Interval Set to Reduce Treatment Burden for nAMD and DME

September 15, 2022

Lowering Treatment Burden and Maintaining Vision Gains with Aflibercept

Server,Room,3d,Illustration,With,Node,Base,Programming,Data,Design

September 3, 2022

EURETINA 2022 LIVE Coverage: Real-World Evidence Registries in Ophthalmology

Embryonic,Stem,Cells,,,Cellular,Therapy,,,Regeneration,,,Disease

August 30, 2022

Cellular Regeneration: Can Selective Retina Therapy and Thermal Stimulation of the Retina be Effective for AMD Treatment?

February 17, 2022

Three New Potential Alternatives to Anti-VEGF

February 11, 2022

FDA Approves First Bispecific Antibody for Eyes

February 9, 2022

Catch Up on the Latest in AMD Management and Treatment

Panic,Cat,Scare,Of,Injection,Syringe,Or,Vaccine.,Risk,Of

February 7, 2022

Aflibercept 8mg Extended Injection Interval Set to Reduce Treatment Burden for nAMD and DME

Lowering Treatment Burden and Maintaining Vision Gains with Aflibercept

EURETINA 2022 LIVE Coverage: Real-World Evidence Registries in Ophthalmology

Aflibercept 8mg Extended Injection Interval Set to Reduce Treatment Burden for nAMD and DME

Lowering Treatment Burden and Maintaining Vision Gains with Aflibercept

Aflibercept 8mg Extended Injection Interval Set to Reduce Treatment Burden for nAMD and DME

Lowering Treatment Burden and Maintaining Vision Gains with Aflibercept

EURETINA 2022 LIVE Coverage: Real-World Evidence Registries in Ophthalmology

Cellular Regeneration: Can Selective Retina Therapy and Thermal Stimulation of the Retina be Effective for AMD Treatment?

Three New Potential Alternatives to Anti-VEGF

FDA Approves First Bispecific Antibody for Eyes

Catch Up on the Latest in AMD Management and Treatment

After a Shot to the Eye: Patient-Reported “Issues” after Intravitreal Injection

Discover our fascinating content at issuu